Regulatory Rapporteur April 2017

<< back to list of Issues

Front Cover
Volume 14 Issue 4

In This Issue

  • FOCUS – Falsified medicines
  • PLUS
  • Developments in the EU referrals procedure: Ten years on Conducting Phase I clinical research in the EU versus US
  • Discussions on the adaptive pathways concept

Please login to view member only articles. Non-members may download the public articles.

Regulatory Rapporteur April 2017MembersFull Issue2MBPDF
Editorial – Falsified medicines: Anything but “fake news”Public492KBPDF
Focus – The Falsified Medicines Directive – What does it really mean for stakeholders?Public544KBPDF
A comparison of UK versus US submission processes for Phase I clinical trial applicationsMembers548KBPDF
A review of developments in the EU referrals procedureMembers596KBPDF
Focus – Insights on falsified medicines in the legal supply chainMembers647KBPDF
Focus – Requirements of the Falsified Medicines Directive’s delegated act on safety featuresMembers545KBPDF
Interview: Investing in qualityMembers695KBPDF
Meeting report: European Medicines Agency’s Adaptive Pathways WorkshopMembers616KBPDF